The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
This is the group’s first NoC approval in Canada
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
Vidya will spark conversations around less discussed and important aspects of health, including intimate care and sleep issues
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
Subscribe To Our Newsletter & Stay Updated
_256_384.JPG)
